Hormonal
Ablation of the PPAR gamma 2 isoform prevents adipose tissue expansion, leading to lipotoxicity, severe insulin resistance, and beta-cell failure despite reduced total fat mass.
This research suggests that metabolic health is not solely determined by how much fat you carry, but by your body's ability to store that fat safely in adipose tissue. If your fat storage capacity is overwhelmed, fat spills over into organs like the liver and pancreas, causing toxicity and insulin resistance regardless of your total body weight. Focus on maintaining metabolic flexibility and healthy adipose tissue function rather than just weight loss.
Ablation of PPARg2 in the ob/ob background... resulted in decreased fat mass, severe insulin resistance, b-cell failure, and dyslipidaemia.
Why this rating
High-quality in vivo mouse model with comprehensive phenotyping and lipidomics.
Source
PPAR gamma 2 Prevents Lipotoxicity by Controlling Adipose Tissue Expandability and Peripheral Lipid Metabolism
Gema Medina‐Gómez et al. · PLoS Genetics · 2007
DOI 10.1371/journal.pgen.0030064
More from this paper
- PPAR gamma 2 prevents lipotoxicity in non-adipose tissues (liver, muscle, pancreas) by facilitating the deposition of fat as harmless triacylglycerols (TAGs) instead of reactive lipid species like ceramides and diacylglycerols (DAGs).Good
- PPAR gamma 2 is required for the adaptive beta-cell hyperplasia and hypertrophy that normally compensates for insulin resistance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →